| Literature DB >> 27585682 |
Sigrun R Hofmann1,2, Anja Schnabel1,2, Angela Rösen-Wolff1,2, Henner Morbach1,2, Hermann J Girschick1,2, Christian M Hedrich3,4.
Abstract
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder, covering a clinical spectrum with asymptomatic inflammation of single bones at the one end, and chronic recurrent multifocal osteomyelitis (CRMO) at the other end. The exact molecular pathophysiology of CNO remains largely unknown. Provided familial clusters and the association with inflammatory disorders of the skin and intestine suggest a genetic predisposition. Recently, profound dysregulation of cytokine responses was demonstrated in CRMO. Failure to produce antiinflammatory cytokines interleukin (IL)-10 and IL-19 contributes to activation of inflammasomes and subsequent IL-1β release. In IL-10-deficient and in CNO-prone chronic multifocal osteomyelitis mice, IL-1β was linked to bone inflammation. Further, alterations to the gut microbiome were suggested in contributing to IL-1β release from innate immune cells in mice, offering an interesting target in the search for molecular mechanisms in CNO. Here, we summarize clinical presentation and treatment options in CNO/CRMO, current pathophysiological concepts, available mouse models, and promising future scientific directions.Entities:
Keywords: CHRONIC NONBACTERIAL OSTEOMYELITIS; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CYTOKINE; INFLAMMATION; TREATMENT
Mesh:
Substances:
Year: 2016 PMID: 27585682 DOI: 10.3899/jrheum.160256
Source DB: PubMed Journal: J Rheumatol ISSN: 0315-162X Impact factor: 4.666